Systemic injection of an adenovirus vector into adult mice resulted in pathological improvements in multiple visceral organs of mice with mucopolysaccharidosis VII; however, no therapeutic efficacy was observed for mental retardation, skeletal deformities, corneal clouding, and retinal degeneration. In this study, an adenovirus vector expressing human bglucuronidase was injected into mice with mucopolysaccharidosis VII within 24 h of birth, and therapeutic efficacy was evaluated. In the brains of the mice, more than 20% of GUSB activity was maintained for at least 20 weeks after birth, and histopathological analysis showed no obvious lysosomal storage. Furthermore, no vacuolated cells were detected in corneal stroma and retinal pigment epithelium in the eyes of the mice treated in the neonatal period, while pathological improvement was not observed in adult MPSVII mice that received similar treatments. The treated mice also lacked characteristic facial skeletal deformities, and radiographic analysis demonstrated that their facial and cranial bones were morphologically normal. These results indicate that a single systemic adenovirus injection in the neonatal period could prevent the progression of mental retardation, corneal clouding, retinal degeneration, and skeletal deformities, all of which are frequently observed clinical manifestations and difficult to treat in adulthood.
Introduction
Mucopolysaccharidosis type VII (MPSVII, Sly disease) is a lysosomal storage disease caused by a systemic deficiency of b-glucuronidase activity. 1 This defect results in a progressive accumulation of undegraded glycosaminoglycans (GAGs) in lysosomes, and affects multiple-tissues or organs simultaneously. B6/MPSVII is a murine model of MPSVII, sharing many pathological and clinical abnormalities with human MPSVII, and both phenotypic and genotypic similarities make this animal model suitable for evaluating novel therapeutic approaches to lysosomal storage disorders. [2] [3] [4] The therapeutic efficacy of bone marrow transplantation (BMT) and enzyme replacement therapy (ERT) for MPSVII has been investigated intensively using the murine model B6/MPSVII, [5] [6] [7] [8] [9] and both therapies are in clinical trials. However, certian socioeconomic and clinical problems have prevented their widespread application. Namely, a shortage of suitable donors often prevents BMT, and the cost for enzyme production and necessity of frequent injection make ERT almost impractical.
As an alternative, gene therapy for MPSVII has been explored using several viral vectors such as retroviruses, [10] [11] [12] herpes viruses, 13, 14 adenoviruses, [15] [16] [17] [18] [19] [20] lentiviruses, 21, 22 and adeno-associated viruses. [23] [24] [25] [26] Both in vivo and ex vivo gene transduction methods have been tested experimentally; however, only limited therapeutic success has been reported, when studies were carried out using adult B6/MPSVII. Although it is clear that a more complete pathological correction can be obtained when ERT or BMT is started from the neonatal period, the efficacy of gene therapy for neonatal MPSVII has not yet been fully investigated.
Daly et al recently reported widespread pathological correction of B6/MPSVII by neonatal gene transfer using an adeno-associated viral (AAV) vector. [27] [28] They generated an AAV vector for expressing human b-glucuronidase under the control of the CAG promoter (a combination of the chicken b-actin promoter and cytomegalovirus enhancer), and injected it into neonatal B6/MPSVII mice. They showed persistent pathological correction in the heart, brain, retina, and liver for at least 16 weeks. However, they also found comparatively low levels of the transgene GUSB activity in all organs following adeno-associated virus-mediated gene transfer. Even at an early time point (2-3 weeks after the treatment), only heart and liver had similar levels of GUSB activity to normal B6 mice, and in the other organs (lung, kidney, brain, and spleen), very little activity (less than 10% of that in normal mice) was detected. Moreover, marked decreases in GUSB activity were observed in the serum, liver, and spleen, and activity levels in all organs except the heart were less than 10% of those in normal mice at 16 weeks after birth. Although they showed sustained therapeutic levels of GUSB (1-5% of normal GUSB levels) in multiple tissues for a year in certain mice, it may be necessary to obtain more efficient transgene expression for the treatment of human MPSVII or other lysosomal storage diseases.
We previously reported the rapid elimination of lysosomal storage in multiple visceral organs of adult B6/MPSVII mice after intravenous administration of an adenovirus-expressing human GUSB. 20 When we injected the adenoviruses into B6/MPSVII via tail veins, they were distributed predominantly in the liver, and over-produced and secreted transgene products were delivered through the systemic circulation into the lung, heart, kidney, and spleen, and subsequent amelioration of lysosomal storage was observed. However, no GUSB expression was observed in the brain, suggesting that viral infection and GUSB transport were both prevented in the brain of adult mice presumably due to blood-brain barriers.
In this study, we administered the adenovirus to newborn B6/MPSVII or normal C3H mice and transgene expression and therapeutic efficacy were observed for 20 weeks. Persistently high levels of GUSB activity were observed for the 20 weeks, and a complete amelioration of lysosomal storage occurred in all organs examined including the brain, cornea, and retina, in the tissues of which, no or little pathological correction was observed in the mice treated in adulthood. We also showed effective secondary administration of adenoviral vectors in the mice treated during the neonatal period. Furthermore, morphological correction of facial and cranial bones was achieved by the neonatal adenoviral treatment.
Results
Distribution of GUSB activity in C3H mice treated with AxCAhGUS as newborns Human b-glucuronidase (GUSB) is heat-stable, and was reduced by only 30% after 2-h incubation at 651C. In contrast, the GUSB of C3H mice is heat-labile, and its activity is almost completely eliminated by the same treatment. 29 Using this difference of heat stability, we evaluated the gene transduction efficiency and distribution of the transgene products by infecting normal C3H mice with adenoviral vectors. Viral solution (100 ml) containing 1 Â 10 7 plaque-forming units (pfu) of AxCAh-GUS (an adenovirus-expressing human GUSB under the control of the CAG promoter) was injected into newborn C3H mice via superficial temporal veins. The mice were sacrificed periodically, and heat-stable GUSB activity was measured in liver, spleen, kidney, lung, heart, and brain ( Figure 1 ). Since the endogenous GUSB level of C3H mice is approximately 10-40% of the GUSB level of Figure 1 Time-dependent change of heat-stable b-glucuronidase (GUSB) activity in normal C3H mice infected with adenovirus-expressing human GUSB (AxCAhGUS). We injected 100 ml of viral solution containing 1 Â 10 7 pfu of AxCAhGUS into newborn normal C3H mice within 24 h of delivery. The mice were sacrificed periodically, and heat-stable GUSB activity in each organ was measured. Each point represents the average and standard deviation for four treated animals. Results are expressed as a percentage of the GUSB activity found in the corresponding organs from four age-matched C57BL6 (B6) mice (a: liver; b: spleen; c: kidney; d: lung; e: heart; f: brain). Seven days after the treatment, high levels of the transgene activity (10-100 times higher than the GUSB activity of age-matched untreated B6 mice) were observed in liver (a), lung (d) and heart (e), while normal levels were detected in spleen (b), kidney (c) and brain (f). A time-dependent decrease of GUSB activity was observed in all examined organs, but more than 5% of the peak levels were still detected at 70 days after the treatment.
Adenovirus injection into neonatal mice with MSPVII Y Kamata et al C57BL6 mice (B6 mice), we calculated '% normal activity' using GUSB level of age-matched normal B6 mice as 100%. Seven days after the treatment, high levels of the transgene (10-100 times the GUSB activity in agematched normal B6 mice) were observed in liver, lung, and heart, while normal levels were detected in spleen, kidney, and brain ( Figure 1) . A time-dependent decrease of GUSB activity was observed in all examined organs, but more than 5% of the peak level was still detected even 70 days after the treatment.
Presence of viral DNA in C3H mice treated with AxCAhGUS
To determine whether the origin of the transgene GUSB in each organ is the result of transgene expression or due to cross-correction of lysosomal GUSB, viral DNA was detected with the PCR-based method (Figure 2 ). The PCR primers were designed based on the sequences of exons 6 and 7 of the human GUSB gene to amplify a 240-bp fragment from the human GUSB cDNA located in the viral genome of AxCAhGUS. This PCR also generates a 454-bp fragment from the endogenous murine GUSB gene. 20, 30 When adult mice were infected with AxCAh-GUS intravenously, a clear 240-bp DNA fragment was only detected in the PCR reaction from liver DNA, suggesting that AxCAhGUS accumulated predominantly in the liver. On the other hand, clear 240-bp DNA fragments were observed in all organs, when AxCAh-GUS was intravenously administered into newborn mice, demonstrating that a significant amount of virus was distributed into multiple organs including the brain. These results indicate that the GUSB activity detected in extra-hepatic organs of the treated adult mice was due to cross-correction of a lysosomal enzyme rather than direct gene transduction; however, direct gene transduction also significantly contributed to GUSB expression in extra-hepatic organs in the mice treated as newborns.
Therapeutic efficacy of neonatal gene therapy in visceral organs
We injected an adenovirus 'AxCAhGUS' into four newborn B6/MPSVII mice and measured GUSB activity in visceral organs 30 days later. Higher than normal levels of GUSB activity (1-50 times higher than normal) were observed in liver, spleen, lung, and heart; approximately, half of the normal activity was observed in kidney ( Figure 3A ). Histochemical study showed disseminated GUSB-positive cells in all visceral organs, which agreed with the result of the quantification of GUSB activity (data not shown). Furthermore, histopathological analysis demonstrated complete morphological normalization in liver and spleen in the mice treated during the neonatal period ( Figure 3B ).
Therapeutic efficacy of neonatal gene therapy in CNS lesions
We previously showed that the intravenous administration of AxCAhGUS into adult mice resulted in significant Figure 2 Detection of virally encoded human GUSB cDNA in mice treated with AxCAhGUS. We injected AxCAhGUS into C3H mice within 24 h of delivery or 30-40 days after birth. Seven days after the treatment, the mice were sacrificed and DNA from several organs was extracted and used as template for PCR. Virally encoded human GUSB cDNA in AxCAhGUS produces a 240-bp band, and the murine GUSB gene produces a 454-bp band. An intense 240-bp band was identified in all organs examined including the brain in the mice treated in the neonatal period (a), while the corresponding band was identified only in the liver in the mice treated at the age of 30-40 days. In each group, four mice were used for this experiment, and representative results are shown. Lane 1: liver; lane 2: spleen; lane 3: kidney, lane 4: lung; lane 5: heart; lane 6: brain. Lane P shows the result of the PCR reaction using human GUSB cDNA as a template. 
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Y Kamata et al levels of GUSB expression in multiple visceral organs; however, no obvious GUSB expression was detected in the brain. 20 Since the results in C3H mice described above suggested that vector infection and subsequent GUSB expression were achievable in the mouse brain by neonatal administration, we injected AxCAhGUS into newborn B6/MPSVII mice, and therapeutic efficacy in CNS lesions was evaluated. Approximately 200% of normal GUSB activity was found in the brain 30 days after the viral injection, and 20-30% of normal GUSB activity was still detected at 140 days ( Figure 4A ). Histochemical study showed that disseminated GUSBpositive cells were distributed in the cortex of the mouse brain (Figure 4Ba ). On the other hand, no GUSB-positive cells were detected in the brain of B6/MPSVII mice treated at 30 days after birth (Figure 4Bc) . Histopathological study demonstrated that no vacuolated cells were detected even 140 days after birth (Figures 4Bd and Be).
Therapeutic efficacy of neonatal gene therapy against ocular complications
Retinal degeneration and corneal clouding are frequently observed as ocular complications in MPSVII or other mucopolysaccharidoses. 31, 32 We studied the therapeutic efficacy in the retina and cornea of B6/MPSVII mice treated by systemic vector administration in the neonatal period. In the retina of the mice treated in adulthood, no or few GUSB-positive cells were identified among the retinal pigment epithelial cells where lysosomal storage is remarkable in the affected mice (Figures 5Aa and Ac). In contrast, these cells were clearly GUSBpositive in the mice treated in the neonatal period, and subsequent improvement of lysosomal storage was observed (Figures 5Ab and Ad). In the cornea, histochemical study indicated that disseminated GUSBpositive cells were present in the stroma, and subsequent amelioration of lysosomal storage was observed (Figures 5Bb and Bd) in the mice treated during the neonatal period. However, no obvious pathological correction was observed in the cornea of the mice treated in adulthood (Figures 5Ba and Bc) . These results show that effective therapeutic results for ocular complications by systemic administration can be obtained only when the injection is carried out in the neonatal period.
Improvement of skeletal deformities by neonatal treatment
Skeletal deformity is another frequent and serious manifestation in patients suffering from all types of mucopolysaccharidoses. A flattened face is a characteristic phenotype of skeletal deformity in B6/MPSVII. All the mice that received neonatal treatment were of normal facial appearance even at 140 days after the treatment, and radiographic analysis showed morphological normalization of facial and cranial bones in the mice treated in the neonatal period ( Figure 6 ). On the other hand, no obvious improvement in skeletal deformities was observed on adenovirus treatment in adult mice (data not shown), suggesting that neonatal or infantile gene therapy is essential for preventing skeletal deformities in MPSVII.
Feasibility of gene transduction by multiple vector administrations
The feasibility of gene transduction by multiple vector administrations was studied by quantification of serum GUSB activity in the MPSVII mice treated in the neonatal period. About 5-10 times higher than normal GUSB activity was observed 35 days after the treatment (Figure 7 ). Since no increase in the titers of antiadenoviral neutralizing antibody was observed in the same serum samples (Table 1) , we attempted a secondary viral administration at 35 days after birth. A rapid and marked increase of serum GUSB activity was identified 7 days after the secondary injection, and this high level of the activity was maintained for more than 100 days after birth (Figure 7) . However, the mice generated significant Adenovirus injection into neonatal mice with MSPVII Y Kamata et al levels of anti-adenoviral neutralizing antibody (32-128 titers) 2 months after the secondary injection (Table 1) . Moreover, no increase of serum GUSB activity was observed 7 days after tertiary vector administration ( Figure 7 ).
Discussion
We previously reported the therapeutic efficacy of adenovirus-mediated gene therapy in adult MPSVII mice. 20 In the report, we demonstrated that high levels of GUSB activity in multiple extrahepatic organs such as spleen, kidney, lung, and heart were the result of in vivo cross-correction of GUSB delivered from the liver, where gene transduction had taken place. A rapid and complete amelioration of lysosomal storage was also observed in liver and spleen in the treated animals. These experiments, however, also disclosed the limitations of this treatment strategy. First, no significant GUSB activity was identified in the brain, which is one of the most important affected regions in MPSVII as well as other 
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Y Kamata et al lysosomal storage disorders. Second, no pathological correction was observed in retina and cornea. Third, no improvement of skeletal deformities was found. Finally, the therapeutic effect did not persist for long. Mental retardation is a frequent manifestation in several types of mucopolysaccharidoses as well as other lysosomal storage disorders. 33 We and other groups achieved successful pathological correction in the CNS by transplantation of GUSB-producing cells, 11, 18 or by generation of GUSB-producing cells in the brain with direct vector administrations. 16 Although these therapeutic strategies may be effective, less invasive approach is required for widespread clinical applications. Sands et al showed that for BMT or ERT, it is necessary to start the treatments in the neonatal period to prevent degenerations of the CNS. 5, 7, 9 Daly et al have recently shown that neonatal gene transfer is also effective for treating the CNS in MPSVII using adeno-associated virus vectors. 27 They showed that the GUSB activity in the brain after AAV-mediated gene transduction was less than 10% of the activity in normal littermates. Although 1-5% of normal activity may be sufficient for the treatment in this particular disease model, a comparatively inefficient gene transduction may cause the problem in the treatment of human MPSVII or other lysosomal storage diseases. In the present study, we demonstrated that 20-30% of normal GUSB activity was detected in the mouse brain even 140 days after the adenovirus treatment. These observations indicate that an adenoviral gene transfer seems to be more efficient than the treatment with AAV vectors, although physiological and behavioral studies will have to be performed to prove this.
The blood-brain barrier is the main reason why both vector infection and GUSB transport were prevented in adult mouse brain. 34 The blood-retinal barrier is also a 
Figure 7
Time-dependent change of serum GUSB activity in the mice treated with AxCAhGUS. To investigate the feasibility of gene transduction by multiple vector injections, we performed periodic serum sampling from the mice infected with AxCAhGUS during the neonatal period. A 10-fold higher than normal GUSB activity was still identified in the mice 5 weeks after the treatment. Secondary vector administration was carried out just after the serum sampling. A week later, serum GUSB activities were measured again. A marked increase in serum GUSB activity was observed, and this high level of activity was maintained for more than 60 days. However, no obvious increase in GUSB activity was observed when a tertiary administration was performed 120 days after the first administration. Each point represents the mean and standard deviation from four treated animals. Results are expressed as a percentage of the GUSB activity in four age-matched B6 (+/+) mice. Arrows indicate the day when the vector injection was done. For the first administration, 100 ml of the vector solution containing 1 Â 10 7 pfu of AxCAhGUS was injected into neonatal B6/MPSVII mice via superficial temporal veins. For secondary and tertiary administration, 1 ml of vector solution containing 1 Â 10 8 pfu of AxCAhGUS was injected into B6/MPSVII mice via tail veins.
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hurdle in the delivery of drug to the cells in the retina from the systemic circulation. 35 In this paper, we have reported that no GUSB-positive cells were detected among retinal pigment epithelial cells, and lysosomal storage was not eliminated in the adult mice treated by adenovirus vectors. This finding suggests that the bloodretinal barrier prevented both vector infection and uptake of GUSB into the retinal pigment epithelial cells. On the other hand, long-term GUSB expression and pathological correction were observed in the mice treated in the neonatal period. Although it is unclear whether the blood-retinal barrier is immature in neonatal mice just like the blood-brain barrier, immaturity of the barriers may have enabled the vector infection to occur in retinal cells. 34 Here, we also showed that lysosomal storage in corneal stroma was completely eliminated in the mice treated during the neonatal period, while no obvious efficacy was seen in the mice treated in adulthood. This finding is unexpected but favorable in terms of treatment of corneal clouding, which is the most frequent ocular manifestation in several types of mucopolysaccharidoses. 33 We also showed improvement of skeletal deformities following neonatal treatment. In the mice treated after maturation, no obvious improvement of facial dysmorphology was achieved. However, the facial appearance of the mice treated in the neonatal period was completely normal. Radiographic analysis showed that their facial and cranial bones were also morphologically normal. These results demonstrate that a single vector injection during the neonatal period is sufficient for complete normalization of the facial and cranial bones in MPSVII.
One of the most important findings in this study is the remarkable difference in vector targeting organs after intravenous injection between neonatal and adult treatment. As we showed previously, most of the vectors were accumulated in the liver when we injected virus in adult mice. 20 On the other hand, the vectors were distributed in all organs examined when injection was carried out in the neonatal period. Fechner et al reported that anatomic vector barriers, in particular the endothelium structure, were the major factors in determining the vector-targeting organs, and the expression of viral receptors did not correlate with adenoviral vector targeting. 36 This suggests that immaturity of the bloodbrain barrier and blood-retinal barrier is a major factor for determining vector-targeting organs, although the difference of the site of injection between newborn MPSVII and adult MPSVII might also partially account for the difference of the vector-targeted organs.
Since an exogenously transduced gene delivered by adenoviral vectors is episomal, dilution of the transgene should take place with the growth of the vector-infected organs or tissues. This indicates the necessity for multiple vector administrations to obtain long-term therapeutic efficacy especially for neonatal treatment. In this report, we demonstrated the feasibility of secondary gene transduction in mice treated initially during the neonatal period. However, anti-adenovirus antibody was generated after secondary treatment, and tertiary injection did not induce efficient gene transduction. These observations suggest that neonatal mice can avoid the deleterious immune response induced by infection with adenovirus vectors. Reducing the immune response that accompanies adenoviral vector infection is essential not only to prolong the transgene expression but also to carry out adenovirus-mediated gene therapy safely.
Here we showed that a single adenoviral infection in the neonatal period is sufficient to prevent the progression of multiple tissue lesions in the CNS, ocular tissues and skeletal system in MPSVII mice. Since humans are rather more developed at birth than mice in terms of the blood-brain barrier, we may have to consider fetal gene therapy (in utero gene therapy) to achieve the similar therpeutic efficacy in human MPSVII. The molecular genetics of lysosomal storage diseases has been intensively investigated, and prenatal diagnosis of lysosomal storage diseases is now available. Although several safety issues have to be resolved before clinical applications, neonatal or fetal treatment with an adenoviral vector combined with prenatal diagnosis is a promising strategy for MPSVII and other lysosomal storage disorders.
Materials and methods

Adenoviruses
The two adenoviruses, AxCAhGUS and AxCALacZ, used in this study were E1/E3-deleted recombinant adenoviruses expressing human b-glucuronidase (GUSB) and E. coli b-galactosidase (lacZ), respectively. 19, 20 Both viruses were generated based on the COS-TPC method described previously. 37 Briefly, a cosmid, pAxCAhGUS, which contained an expression cassette of human GUSB under the control of the CAG promoter, 38 was constructed by subcloning cDNA for human GUSB at a unique SwaI site of pAxCAwt. Then 293 cells were co-transfected with the cosmid pAxCAh-GUS and an adenoviral DNA-terminal protein complex, which had already been digested at several sites with EcoT22I. A recombinant adenovirus was generated through homologous recombination in the transfected cells. Another adenoviral vector AxCALacZ was supplied by Dr I Saito. 39 
Animals
Syngeneic B6/MPSVII mice were obtained from a pedigree colony of B6.C-H-2bml/ByBir-gusmps/+ mice maintained at the National Children's Medical Research Center. 2, 3 Normal C3H mice were purchased from Shizuoka Laboratory Animal Center (Shizuoka, Japan). All mice were maintained in accordance with the guidelines of the animal committee of the facility.
Neonatal injections
Viral solution (100 m1) containing 1 Â 10 7 pfu of AxCAh-GUS was injected into newborn B6/MPSVII mice (n¼8) 
Detection of viral DNA in mouse organs
The total DNA of tissue samples was extracted using a QIAamp DNA mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol. Viral DNA in each tissue was detected using PCR to amplify the partial cDNA for human GUSB based on a method described previously. 20 Briefly, the forward and reverse primers were synthesized from the sequence of exons 6 and 7. Expected products are 240-bp fragments from human cDNA encoded in the viral genome of AxCAh-GUS. Since these primer sequences were identical to the corresponding regions of the murine GUSB gene with two mismatches, 454-bp DNA fragments were amplified when PCR was carried out using mouse genomic DNA as template.
Quantitative and histochemical analysis of GUSB activity GUSB activity in tissue was quantified using a fluorometric assay described previously. 40 Briefly, tissues were homogenized in 10 mM Tris-HCI (pH 7.5), 150 mM NaCl, 0.2% Triton X-100, and 1 mM dithiothreitol. When necessary, the samples were incubated for 2h at 651C to inactivate endogenous GUSB in normal C3H mice. GUSB activity was measured using 4-methylumbelliferyl b-Dglucuronide (Sigma, St. Louis, MO, USA) as substrate. Histochemical detection of GUSB activity was performed on 6-mm-thick frozen sections using naphtol AS-BI b-Dglucuronide (Sigma) as substrate. Tissues were then counterstained with methyl green (Muto Chemistry, Tokyo, Japan).
Histopathological analysis of lysosomal storage
Tissues were isolated from the mice, and immediately immersed in cold 2% glutaraldehyde in 0.1 M. cacodylate buffer, postfixed in 1% osmium tetroxide, dehydrated through a graded series of ethanol solutions, and embedded in Spurr's Medium (Polyscience, Warrington, PA, USA). Three micrometers thick frozen section were stained with toluidine blue for evaluation of lysosomal storage. Histological sections were evaluated morphologically by light microscopy. 18 
Anti-adenoviral neutralizing antibodies
Anti-adenovirus neutralizing antibodies in serum were measured as described previously with minor modifications. 41 Briefly, the serum samples were heat-inactivated at 551C for 30 min and diluted in the medium in two steps. Each serum dilution (0.1 ml) was mixed with 5 Â 10 5 pfu of AxCALacZ (10 m1), incubated at 371C for 90 min, and applied to nearly confluent 293 cells in a 96-well plate for 10 h. The supernatant, containing serum and viruses, was then replaced with normal medium for 18h. Cells were fixed and stained with X-gal. In the absence of neutralizing antibody, all of the cells stained blue. Titers of the neutralizing antibody for each serum sample were reported as the highest dilution at which less than 25% of the cells stained blue.
